COMMUNIQUÉS West-GlobeNewswire
-
Celldex to Present at Upcoming Investor Conferences
09/02/2026 -
Carterra Launches Industry’s First 48-channel HT-SPR Platform for Advanced Label-free Biomolecular Screening and Characterization
09/02/2026 -
Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping
09/02/2026 -
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
09/02/2026 -
Voyager to Present at Upcoming Investor Conferences
09/02/2026 -
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
09/02/2026 -
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/02/2026 -
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
09/02/2026 -
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/02/2026 -
Omada Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 5, 2026
09/02/2026 -
Trained Therapeutix Discovery Appoints Distinguished Industry Leaders to its Board of Directors
09/02/2026 -
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
09/02/2026 -
Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
09/02/2026 -
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
09/02/2026 -
The Oxford-Harrington Rare Disease Centre Advances Discovery of Therapies for Friedreich’s Ataxia (FA)
09/02/2026 -
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
09/02/2026 -
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
09/02/2026 -
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
09/02/2026 -
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
Pages